Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy

Abstract Gadolinium (Gd) and Gd-based contrast agents (GBCAs) have been observed to deposit in tissues of patients following multiple contrast enhanced MR imaging procedures. A conservative approach for chelation therapy of this toxic metal dictates the assumption that minimal intact GBCAs is presen...

Full description

Saved in:
Bibliographic Details
Published in:Magnetic resonance imaging 2016-12, Vol.34 (10), p.1391-1393
Main Authors: Prybylski, John P, Semelka, Richard C, Jay, Michael
Format: Article
Language:English
Subjects:
Chelation
Contrast Media - metabolism
Decorporation
Gadolinium
Gadolinium - metabolism
Image Enhancement
Magnetic Resonance Imaging
Pharmacokinetics
Radiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Gadolinium (Gd) and Gd-based contrast agents (GBCAs) have been observed to deposit in tissues of patients following multiple contrast enhanced MR imaging procedures. A conservative approach for chelation therapy of this toxic metal dictates the assumption that minimal intact GBCAs is present. Currently the extent to which these deposits are primarily de-chelated Gd remains uncertain, prevailing knowledge suggest that for linear agents much of the Gd is de-chelated, while for the macrocyclic agents, the Gd may be still largely chelated. To extract Gd from tissues and facilitate its release, chelation therapy should be both safe and effective. Here we discuss chelation therapy as it relates to Gd deposition. The principles of chelation are reviewed, initially with reference to ligand stability in complex biological fluids. A model of decorporation and how it relates to elimination of Gd deposits is also reviewed. When more is learned about Gd deposition, optimal removal strategies must be developed using basic thermodynamic and kinetic principles.
ISSN:0730-725X
1873-5894
DOI:10.1016/j.mri.2016.08.001